HLA-C and cancer: When the MHC mismatch between BALB/c CTLs and B16F10 cancer cells was utilized for a cytotoxic test40,41, Mg2+ (or Fe3+)-treated CTLs exhibited an enhanced killing capacity to targets (B16F10 cancer cells) in a 2-h killing assay (Fig. 4d).